Drug-related morbidity and mortality: updating the cost-of-illness model.
about
A curated and standardized adverse drug event resource to accelerate drug safety researchMedication-related problem type and appearance rate in ambulatory hemodialysis patientsPatient Participation and the Use of Ehealth Tools for PharmacoviliganceRoutine deprescribing of chronic medications to combat polypharmacyAwareness and knowledge among internal medicine house-staff for dose adjustment of commonly used medications in patients with CKDPrevalence of the prescription of potentially interacting drugsAdverse drug reaction prediction using scores produced by large-scale drug-protein target docking on high-performance computing machinesGeneralized enrichment analysis improves the detection of adverse drug events from the biomedical literatureElective course on medication therapy management servicesPilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Understanding barriers to optimal medication management for those requiring long-term dialysis: rationale and design for an observational study, and a quantitative description of study variables and data.T3DB: the toxic exposome database.A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.Dispensed drugs and multiple medications in the Swedish population: an individual-based register study.Data visualization speeds review of potential adverse drug events in patients on multiple medications.Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression.New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication managementRacial disparities in the quality of medication use in older adults: baseline findings from a longitudinal study.Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach.Medication-related visits in a pediatric emergency department: an 8-years retrospective analysis.Evaluation of specialized medication packaging combined with medication therapy management: adherence, outcomes, and costs among Medicaid patientsDrugs with narrow therapeutic index as indicators in the risk management of hospitalised patients.The contribution of a clinical pharmacist to the improvement of medication at a geriatric hospital unit in NorwayClereMed: Lessons Learned From a Pilot Study of a Mobile Screening Tool to Identify and Support Adults Who Have Difficulty With Medication Labels.Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines.Reducing medication errors in critical care: a multimodal approach.A randomized, controlled pragmatic trial of telephonic medication therapy management to reduce hospitalization in home health patients.Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings.Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study.Incidence of Potential Drug-Drug Interaction and Related Factors in Hospitalized Neurological Patients in two Iranian Teaching Hospitals.Report of the 2009-2010 standing committee on advocacy.Pharmacists' contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers.Provision of medication therapy management to university faculty and staff members by third-year pharmacy studentsPersonalizing health care: feasibility and future implications.Assessment of drug-related problems in depressive patients.Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China.Enhancing community pharmacy through advanced pharmacy practice experiences.Racial disparities in quality of medication use in older adults: findings from a longitudinal study.Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia.The Use of Complementary and Alternative Medicine among Lebanese Adults: Results from a National Survey
P2860
Q24658583-DEE1F364-CDF1-4956-B6ED-73AE7602A935Q24805292-05CF39C5-A290-4429-B23F-F55E3A793E07Q26752684-10EF665D-7E8D-4A7B-89FE-ABA8C0D5FDC6Q26775802-1BF9B1B9-AD8F-45C6-9F31-24E63803CF7FQ28468296-8E4BCD05-4F27-4E3D-82FE-441A4C14A543Q28534352-CB3F1487-9E65-444C-9FB9-6C2194889EE3Q28542829-6A00D709-608D-46F9-A1F3-65FF8DC93E62Q28829259-8A24B92F-173F-44E5-839B-2A55C4647A4BQ30227154-326C9FC2-2931-4F70-A5FF-4543339FD48EQ30612258-680E5935-7EB5-41A9-A680-3DF7C01BB2BEQ30657472-B3B89EF6-108C-49AB-8468-42CE5D90200BQ30868311-62F6C711-7E6B-4DC3-92BC-31BA3A193834Q30979182-47742C5A-3F1C-4D57-8B5C-4C0049116041Q33453909-C8D30757-AE15-48FC-8080-2FF24BA86DBFQ33517576-AE7993EC-763A-4F18-B1CF-52183418B211Q33570878-24A61EDF-9E49-489E-9905-017595465364Q33577423-1E55313A-62A3-4EB0-9B7E-9104FAD7A5F8Q33730851-4320E6AD-825C-4490-9859-352AB2CF9228Q33792583-2CBF605A-014E-4C6F-8550-D45A9DBAA496Q33796209-0F20FEFD-1DBF-445D-A700-E44422400023Q34019299-D68235BB-0DBF-4C67-965F-532574457616Q34074885-771BAFA7-EE3C-4FB2-8BDC-E3116E8E6F56Q34100728-CC3B25A6-DC4B-41E6-803C-D0A18EF9B6E0Q34102373-81168007-B096-4AF5-90E1-70A8C1E17E45Q34131674-8DBC4C82-E0A6-4749-92C3-BDFBF427C337Q34140686-D10C9D06-4E09-48F1-92AF-6EBBAF7D0CCFQ34255393-4DBE9EEB-F5AB-4FB9-A3AE-3DB35BEBB642Q34474955-70C225C1-102B-425B-B3C5-20BE57B1115CQ34536946-CDE177AE-D8DD-4679-BB42-C20AF3A75198Q34567387-F1F5633A-ACCF-470B-BCBA-F48C71CF4C7EQ34680606-1505CCE6-8F96-4935-9E2E-4F25F02A605DQ34680652-A8A0FC7D-33B3-4F52-807E-AB3A95467CB7Q34680697-0EB48FA0-0C7A-467E-98FB-2A1503A370B2Q34938911-A85798CE-9177-4560-89D4-6F56A572B502Q35041625-56998677-5FD4-42B8-8034-534ACF1F4E04Q35095945-0FCDCB64-5905-4F59-B539-5DCB1D590198Q35131796-D61635F5-5146-4C08-9D5E-8BF411FD3976Q35154065-DF262219-16AD-43FE-98A7-AEC91458C463Q35573267-143E9EBD-E3A2-4868-9703-C51A90F5FEF7Q35708417-2EFC50AC-4D8B-481B-ABEC-26313F608554
P2860
Drug-related morbidity and mortality: updating the cost-of-illness model.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Drug-related morbidity and mortality: updating the cost-of-illness model.
@en
Drug-related morbidity and mortality: updating the cost-of-illness model.
@nl
type
label
Drug-related morbidity and mortality: updating the cost-of-illness model.
@en
Drug-related morbidity and mortality: updating the cost-of-illness model.
@nl
prefLabel
Drug-related morbidity and mortality: updating the cost-of-illness model.
@en
Drug-related morbidity and mortality: updating the cost-of-illness model.
@nl
P1476
Drug-related morbidity and mortality: updating the cost-of-illness model
@en
P2093
A J Grizzle
P304
P356
10.1016/S1086-5802(16)31229-3
P577
2001-03-01T00:00:00Z